Avalo Therapeutics (NASDAQ:AVTX) just reported results for the second quarter of 2024.
- Avalo Therapeutics reported earnings per share of -$14.07. This was below the analyst estimate for EPS of -$6.70.
- The company did not report any revenue for the quarter.